Chimeric antigen receptors (CARs) are genetically engineered cells that are developed in the laboratory and infused into a patient to help in detecting and fighting cancer. CAR-T cell therapy is defined as a type of immunotherapy that teaches T cells to recognize and destroy cancer.
The CAR-T Cell Therapy market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.

Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.

In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the CAR-T Cell Therapy industry.
Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy.

The CAR-T Cell Therapy market can be split based on product types, major applications, and important countries as follows:

Key players in the global CAR-T Cell Therapy market covered in Chapter 12:
Novartis International AG
Kite Pharma, Inc. (Gilead Sciences, Inc.)
Legend Biotech (Genscript Biotech Corporation)
CARsgen Therapeutics, Ltd.
Mustang Bio, Inc.
Sorrento Therapeutics Inc.
Celgene Corporation
Pfizer, Inc.
Aurora Biopharma Inc

In Chapter 4 and 14.1, on the basis of types, the CAR-T Cell Therapy market from 2015 to 2025 is primarily split into:
CD 19
CD 20
GD2
CD22
CD30
CD33
HER1
HER2
Meso
EGFRvlll

In Chapter 5 and 14.2, on the basis of applications, the CAR-T Cell Therapy market from 2015 to 2025 covers:
Acute Lymphocytic
Leukemia
Chronic Lymphocytic Leukemia
Non Hodgkin Leukemia
Multiple Myeloma
Pancreatic Cancer
Neuroblasta
Breast Cancer
Acute Myeloid Leukemia
Hepatocellular Carcinoma
Colorectal Cancer

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 6, 7, 8, 9, 10, 11, 14:
North America (Covered in Chapter 7 and 14)
United States
Canada
Mexico
Europe (Covered in Chapter 8 and 14)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 9 and 14)
China
Japan
South Korea
Australia
India
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 10 and 14)
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Others
South America (Covered in Chapter 11 and 14)
Brazil
Argentina
Columbia
Chile
Others

Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025